Pandemic preparedness research and biocontainment infrastructure at The Rockefeller University

洛克菲勒大学的流行病防范研究和生物防护基础设施

• 批准号: 10611639
• 负责人: Timothy O'Connor
• 金额: $ 701.94万
• 依托单位: ROCKEFELLER UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-16 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10611639
• 关键词: 2019-nCoV; Address; Alphavirus; Animal Model; Antibodies; Antiviral Agents; Appointment; Award; Baltimore; Binding; Biochemistry; Biology; COVID-19 pandemic; Cell Culture System; Cell Culture Techniques; Cells; Cessation of life; Chemistry; Chikungunya virus; Communicable Diseases; Containment; Coronavirus; Development; Equipment; Faculty; Flavivirus; Foundations; Future; Generations; Genes; Genetic; Grant; HIV; HIV-1; Head; Hepadnaviridae; Hepatitis B Virus; Hepatitis C; Hepatitis C virus; Hepatitis C-Like Viruses; Hospitals; Human; Human Resources; Immune response; Immunology; In Vitro; Influenza; Infrastructure; Institution; Intervention; Laboratories; Leadership; Medicine; Modernization; Monoclonal Antibody Therapy; Nobel Prize; Oncogenes; Orthomyxoviridae; Parasites; Peer Review; Pharmacotherapy; Play; Powassan virus; Predisposition; Proteins; Publications; RNA Viruses; RNA-Directed DNA Polymerase; Rattus norvegicus; Recording of previous events; Replicon; Reproduction; Research; Research Activity; Research Personnel; Resolution; Resources; Retroviridae; Rice; Risk; Rivers; Role; SARS-CoV-2 infection; SARS-CoV-2 spike protein; Safety; Seminal; Solid Neoplasm; System; United States National Academy of Sciences; Universities; Vaccines; Variant; Vesicular stomatitis Indiana virus; Viral; Virus; Virus Diseases; Virus Replication; West Nile virus; Work; Yellow Fever; ZIKA; animal facility; antiretroviral therapy; base; biocontainment facility; biosafety level 3 facility; chikungunya; experience; graduate student; human coronavirus; in vivo; insight; instrumentation; neutralizing antibody; novel; operation; pandemic disease; pandemic preparedness; pathogen; structural biology; virology; virus tropism

Project Summary/Abstract Rockefeller University is a unique institution: with only 70 Heads of Laboratories, the faculty have received 3 Nobel prizes in Medicine in the last 10 years and 5 (plus 1 in chemistry) in the last 21 years, along with appointment of 18 faculty as HHMI investigators and 29 to membership in the National Academy of Sciences. Rockefeller faculty have played an outsized role in contributions to foundational discoveries in virology and infectious disease, both historically and presently. Recognizing the importance of the current pandemic, over the past two years, a dozen research groups at Rockefeller have joined the research efforts focused on pandemic threat viruses, with numerous grants supporting the work and over 50 peer-reviewed publications to date. Rockefeller labs have made seminal contributions identifying the spectrum of neutralizing antibodies to the SARS-CoV-2 spike protein, the impact of variants on neutralization, and characterizing the atomic- resolution binding of antibodies to spike protein. Collectively, Rockefeller laboratories are working on Alphaviruses (e.g., Sindbis, chikungunya viruses), Flaviviruses (e.g., yellow fever, Zika, West Nile, Powassan viruses), Hepaciviruses (hepatitis C virus, Norway rat hepacivirus), Hepadnaviruses (hepatitis B virus), Orthomyxoviruses (influenza), Coronaviruses (SARS-CoV-2 and other human coronaviruses) and retroviruses including HIV-1. Many of the viruses under study, including chikungunya, yellow fever, West Nile, Powassan, and SARS-CoV-2, are classified as Risk Group 3 (RG3) pathogens, requiring BSL3 containment facilities and practices. Moreover, some research at Rockefeller includes the generation of replicons and chimeric (VSV- based) viruses whose stability and safety should be established under BSL3 conditions prior to use at lower biosafety containment levels. This project seeks to enhance and expand space and support for both in vivo and in vitro research. Specific aim 1 is to increase the Rockefeller University’s BSL3 capacities to meet the scientific needs by establishing a new BSL3 facility in an existing laboratory building. Specific aim 2 is to equip and enhance the new facility and the BSL3/ABSL3 facilities that already exist at the University. To achieve these aims, an extremely experienced team of personnel at Rockefeller propose to: establish a new multiple- investigator BSL3 facility; add equipment to the existing single-PI BSL3 facility; replace an existing autoclave and add an incremental autoclave in the ABSL3; and modernize the supporting infrastructure in the ABSL3.

项目总结/摘要 洛克菲勒大学是一个独特的机构：只有70个实验室负责人，教师收到了3个 在过去的10年中，诺贝尔医学奖和5个（加上1个化学奖）在过去的21年中，沿着 任命18名教师为HHMI调查员，29名教师为国家科学院成员。 洛克菲勒大学的教师在对病毒学和生物学的基础发现做出贡献方面发挥了巨大作用， 传染病，无论是历史上还是现在。认识到当前大流行病的重要性， 在过去的两年里，洛克菲勒的十几个研究小组加入了研究工作，重点是 大流行威胁病毒，有许多赠款支持工作和50多个同行评审的出版物， 约会洛克菲勒实验室在确定中和抗体谱方面做出了开创性的贡献， SARS-CoV-2刺突蛋白，变异体对中和作用的影响，以及表征 抗体与刺突蛋白的分辨结合。洛克菲勒实验室正致力于 甲病毒（例如，辛德毕斯，基孔肯雅病毒），黄病毒（例如，黄热病、寨卡病毒、西尼罗河病毒、波瓦桑病毒 病毒），肝炎病毒（丙型肝炎病毒，挪威大鼠肝炎病毒），嗜肝DNA病毒（肝炎B病毒）， 正粘病毒（流感）、冠状病毒（SARS-CoV-2和其他人类冠状病毒）和逆转录病毒 包括HIV-1。许多正在研究的病毒，包括基孔肯雅病毒、黄热病、西尼罗河病毒、波瓦桑病毒， 和SARS-CoV-2被列为风险组3（RG 3）病原体，需要BSL 3遏制设施， 实践此外，洛克菲勒的一些研究包括复制子和嵌合体（VSV-1）的产生。 的）病毒，其稳定性和安全性应在BSL 3条件下确定，然后在较低温度下使用 生物安全遏制水平。该项目旨在加强和扩大空间和支持， 和体外研究。具体目标1是增加洛克菲勒大学的BSL 3能力，以满足 通过在现有实验室大楼中建立新的BSL 3设施来满足科学需求。具体目标2是装备 并加强新的设施和BSL 3/ABSL 3设施已经存在的大学。实现 为了实现这些目标，洛克菲勒的一个经验丰富的团队建议：建立一个新的多功能， 研究者BSL 3机构;为现有的单一PI BSL 3机构增加设备;更换现有的高压灭菌器 并在ABSL 3中增加一个增量高压灭菌器;并使ABSL 3中的支持基础设施现代化。